Another top exec leaves J&J unit; Lilly gets fibromyalgia use for Cymbalta;

> Worldwide president of Johnson & Johnson's Cordis unit--the stent-maker--announced he's leaving the company as of July 11, becoming the seventh senior exec at Cordis to announce an exit in recent months. Report

> Eli Lilly has received governmental approval to use its anti-depression drug Cymbalta on a new class of patients: those with fibromyalgia. Report

> Struggling drug developer Skyepharma rallied as the US authorities gave approval to GlaxoSmithKline's once-a-day Parkinson's treatment Requip XL, which uses Skyepharma's technology.Report

> The FDA gave the nod to Lupin's version of the Forest Laboratories antidepressant Lexapro, for distribution post-patent in 2012. Report

> To restrain pharmaceutical companies from escaping price controls by tweaking the pack size and strength of their price-controlled brands, India has introduced "pro-rata pricing" to standardize costs across formulations and dosage strengths. Report

> Abbott has opened a new Formulation Development Center at its Illinois headquarters. At the R&D facility, researchers will take candidate molecules and formulate them into tablets and capsules for use in in pre-clinical and clinical studies. Report

> CRO Parexel has made a $182 million bid for U.K.-based ClinPhone, but it may be facing competition from Quintiles, the world's largest private CRO. Report

> As the battle for Biovail continues, current CEO William Wells emphasized the company's focus on CNS drug development at Goldman Sachs' annual healthcare conference. Biovail is investing $600 million over the next four years for work on epilepsy, multiple sclerosis, and Parkinson's. Report

> Outside experts are preparing to review ustekinumab, Centocor's injectable treatment for severe psoriasis. Report

> A recent report by Credit Suisse analysts found that investing in medical nanotechnology could have a real payoff in the coming years. Report

Emerging Drug Developer: Itero Biopharmaceuticals 

And Finally... High levels of the "hunger hormone" ghrelin have an antidepressant effect, researchers claim. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.